Agúndez JA - Search Results

1

Expression in human prostate of drug- and carcinogen-metabolizing enzymes: association with prostate cancer risk.

Agúndez JA, Martínez C, Olivera M, Gallardo L, Ladero JM, Rosado C, Prados J, Rodriguez-Molina J, Resel L, Benítez J. Agúndez JA, et al. Br J Cancer. 1998 Nov;78(10):1361-7. doi: 10.1038/bjc.1998.685. Br J Cancer. 1998. PMID: 9823980 Free PMC article.

2

Genetic analysis of the arylamine N-acetyltransferase polymorphism in breast cancer patients.

Agúndez JA, Ladero JM, Olivera M, Abildúa R, Román JM, Benítez J. Agúndez JA, et al. Oncology. 1995 Jan-Feb;52(1):7-11. doi: 10.1159/000227419. Oncology. 1995. PMID: 7800347

3

CYP2D6 genes and risk of liver cancer.

Agúndez JA, Ledesma MC, Benítez J, Ladero JM, Rodríguez-Lescure A, Díaz-Rubio E, Díaz-Rubio M. Agúndez JA, et al. Lancet. 1995 Apr 1;345(8953):830-1. doi: 10.1016/s0140-6736(95)92965-7. Lancet. 1995. PMID: 7898230

4

Molecular analysis of the arylamine N-acetyltransferase polymorphism in a Spanish population.

Agúndez JA, Martínez C, Olivera M, Ledesma MC, Ladero JM, Benítez J. Agúndez JA, et al. Clin Pharmacol Ther. 1994 Aug;56(2):202-9. doi: 10.1038/clpt.1994.124. Clin Pharmacol Ther. 1994. PMID: 8062497

5

Lung cancer and mutations at the polymorphic NAT2 gene locus.

Martínez C, Agúndez JA, Olivera M, Martín R, Ladero JM, Benítez J. Martínez C, et al. Among authors: agundez ja. Pharmacogenetics. 1995 Aug;5(4):207-14. Pharmacogenetics. 1995. PMID: 8528267

6

CYP2D6 genotypes in Spanish women with breast cancer.

Ladona MG, Abildúa RE, Ladero JM, Román JM, Plaza MA, Agúndez JA, Muñoz JJ, Benítez J. Ladona MG, et al. Among authors: agundez ja. Cancer Lett. 1996 Jan 19;99(1):23-8. doi: 10.1016/0304-3835(95)04033-1. Cancer Lett. 1996. PMID: 8564925

7

Identification and prevalence study of 17 allelic variants of the human NAT2 gene in a white population.

Agúndez JA, Olivera M, Martínez C, Ladero JM, Benítez J. Agúndez JA, et al. Pharmacogenetics. 1996 Oct;6(5):423-8. Pharmacogenetics. 1996. PMID: 8946474

8

Increased risk for hepatocellular carcinoma in NAT2-slow acetylators and CYP2D6-rapid metabolizers.

Agúndez JA, Olivera M, Ladero JM, Rodriguez-Lescure A, Ledesma MC, Diaz-Rubio M, Meyer UA, Benítez J. Agúndez JA, et al. Pharmacogenetics. 1996 Dec;6(6):501-12. doi: 10.1097/00008571-199612000-00003. Pharmacogenetics. 1996. PMID: 9014199

9

CYP2D6, NAT2 and CYP2E1 genetic polymorphisms in nonagenarians.

Agúndez JA, Rodríguez I, Olivera M, Ladero JM, García MA, Ribera JM, Benítez J. Agúndez JA, et al. Age Ageing. 1997 Mar;26(2):147-51. doi: 10.1093/ageing/26.2.147. Age Ageing. 1997. PMID: 9177672

10

Influence of genetic admixture on polymorphisms of drug-metabolizing enzymes: analyses of mutations on NAT2 and C gamma P2E1 genes in a mixed Hispanic population.

Martínez C, Agúndez JA, Olivera M, Llerena A, Ramirez R, Hernández M, Benítez J. Martínez C, et al. Among authors: agundez ja. Clin Pharmacol Ther. 1998 Jun;63(6):623-8. doi: 10.1016/S0009-9236(98)90085-6. Clin Pharmacol Ther. 1998. PMID: 9663176

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

291 results

Search Page